Nuacht

ACIP voted to recommend against anyone — adult, child and pregnant person — receiving a seasonal flu vaccine with the mercury ...
In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...
Zacks Investment Research on MSN1 uair an chloig
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...
By Robin Respaut and Maggie Fick SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, ...
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...
GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have ...
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.
Health news includes a cyberattack affecting patient care in London, Walgreens' financial success amid strategic changes, ...
Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.
If you’ve been waiting for the chance for weight loss injections to drop in price, there are more options turning up to ...
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...